Study S000509

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06499857
Acronym: SEMINAL-AF
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: RECRUITING
Enrollment: 200
Start: 2025-04-14
Primary completion: 2027-12
Lead sponsor: University of Chicago
Conditions: Overweight or Obesity; Atrial Fibrillation
Interventions: DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Time to first AF event detected by routine outpatient monitoring [Baseline to Week 68]
Change from baseline in AF burden detected by routine outpatient monitoring. [Baseline to Week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.